Member Info for Richob

Not sure people realise that you can read their previous posts, Timster.

Onwards Avacta.

Welcome back, Ticino.

Why do you think all employees have share options that are stopping them buying more shares?

In a previous job I had share options, was in the sharesave scheme and still bought more shares as I believed the share price would go upwards, which it subsequently did by a large degree.

There is a limit to employee options due to tax implications so employees that think the company is/ is going to do well would logically buy more.

How do you know that some buys (or sells) today aren't by employees (Directors excluded)?

Just asking.

Onwards Avacta.

... the next AVA6000 update, which could easily send this skyward, Timster has rightly pointed out some other avenues that could well generate welcome news before then.

I think it is worth adding Affyxell to that list.

The recent GenProScriptBio RNS hasn't perhaps received the attention it deserved.

The previous Affyxell RNS said that the affimer for the first target had been achieved and was being transferred to Affyxell.

Given that GSPB are the manufacturer for the first product, it would seem strange to add future manufacturing and also agree to add financing to Affyxell if they weren't confident.

Just another additional avenue.

Onwards Avacta.

Mr A,

I agree with bein. There are numerous exclusion criteria for the trial. Do you really think that Avacta would run a trial, or be allowed to run a trial, if they were thought to be unaware of anything that might impact patients negatively?

Have a think about it.

Onwards Avacta.

Toastie,

A longish read but should explain FAP:

https://www.frontiersin.org/articles/10.3389/fonc.2021.648187/full

All the best.

Onwards Avacta.

There's a starter for ten if you scroll down and find it.

Onwards Avacta.

Worth a read:

https://www.frontiersin.org/articles/10.3389/fonc.2022.854658/full

Onwards Avacta.

https://www.frontiersin.org/articles/10.3389/fonc.2021.648187/full

If you scroll down to expression of FAP in tumours, I think it answers the question about how much FAP is in non cancerous cells.

Onwards Avacta.

Avacta are fully aware of the side effects of doxorubicin, hence the trial of AVA6000, which is a delivery system intended to reduce/eliminate any side effects of doxorubicin.

A detailed read of what is being measured in the clinical trial confirms this.

The Safety Committee, on the data to date, have allowed the dosage to be doubled.

It has therefore worked and the real question now is how well has it worked?

This is from the last RNS:

"AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein a (FAP) which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression."

The next data read out will send this global.

Onwards Avacta.

Getting too predictable, Timster.

Onwards Avacta.

Stodgy. I doubt they will.

Surely part of the point about AVA6000 is that it targets the tumour and not other organs?

Otherwise, there is no point.

It seems that AVA6000 is a bit misunderstood by some and the Safety Committee have agreed an increased dosage.

I am very happy with the Safety Committee's decision and believe that this means that " it works".

Hence I continue to buy when funds allow.

Onwards Avacta.

Rememdering that is fine, Stodgy.

Was it dox? Was it ava6000? Was it anything at all?

Rich OB.

How many unsubstantiated posts would you like to make?

Either put a link on/ grow up/ realise that you are posting rubbish.

No offence intended but you never post anything positive about a share you are allegedly invested in.

Onwards Avacta.

... have LG Chem renewed their license for $2m?

https://www.biospace.com/article/releases/lg-chem-renews-license-triggering-payment-to-avacta/

Can't see a massive pharma doing this without a reason or three.

Onwards Avacta.

... boxxocks posts arriving I see.

Onwards Avacta.

Gen Script Bio think so.

Not only have they agreed to future manufacturing, they have agreed to take part in the next Affyxell funding round as well.

Don't think "the market" understands this and probably don't understand Avacta either.

More shots on goal than the England women's football team need to win the Euros.

Onwards Avacta and only 0.5p down on yesterday's close.

Not a bad explanation of Affyxell:

http://affyxell.com/technology/tech.php

Onwards Avacta.

No RNS.

Does that mean we should go up today?

Onwards Avacta.

Great link, Timster.

Onwards Avacta.

I know you dont get it but the "ignore the clowns" thread included you.

If you don't like the fact that the UK sites are recruiting for this trial, or that AVA3996 is proceeding, then just sell up (if you have any shares) and leave us "poor fools" alone.

I won't be reading your reply as I am now green boxing you along with a few others that clearly can't read.

Onwards Avacta.